Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDUS-2: AUR101 in moderate-to-severe psoriasis
NCT04207801Phase 2Completed
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AUR101 in plaque psoriasis, sponsored by Aurigene Pharmaceutical Services Limited. Started Jan 2020; status: completed.
02
Drugs
AUR101
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04207801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207801.